

1 STATE OF OKLAHOMA

2 2nd Session of the 60th Legislature (2026)

3 SENATE BILL 2024

By: Deever

6 AS INTRODUCED

7 An Act relating to pharmaceutical products; defining
8 terms; requiring manufacturers of pharmaceutical
9 products to publish certain list of ingredients;
10 specifying certain inclusions; clarifying
11 applicability; requiring certain submission and
12 publication; providing administrative, civil, and
13 criminal penalties and remedies; granting certain
14 protection; requiring establishment of certain
15 reporting system; preempting certain rulemaking;
16 providing certain construction; providing for
17 codification; and providing an effective date.

18 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

19 SECTION 1. NEW LAW A new section of law to be codified
20 in the Oklahoma Statutes as Section 9002.1 of Title 63, unless there
21 is created a duplication in numbering, reads as follows:

22 As used in this act:

23 1. "Ingredient" includes:

24 a. all active and inactive components,
25 b. biological materials, such as mRNA, DNA from human or
26 animal sources, and viral vectors,

1 c. synthetic materials, including lipids, nanotechnology
2 components, and polymers, and
3 d. adjuvants, preservatives, stabilizers, and other
4 additives;

5 2. "Manufacturer" means any person or entity engaged in the
6 production, preparation, propagation, compounding, or processing of
7 pharmaceutical products, as defined in Section 353.1 of Title 59 of
8 the Oklahoma Statutes; and

9 3. "Pharmaceutical product" means any drug or device as defined
10 in Section 353.1 of Title 59 of the Oklahoma Statutes including
11 prescription drugs, over-the-counter medications, vaccines, and
12 products intended for research purposes.

13 SECTION 2. NEW LAW A new section of law to be codified
14 in the Oklahoma Statutes as Section 9002.2 of Title 63, unless there
15 is created a duplication in numbering, reads as follows:

16 A. Manufacturers of pharmaceutical products, including those
17 intended exclusively for research purposes, shall publish a complete
18 and detailed list of all ingredients for each product.

19 1. The list shall include:

20 a. the chemical and common names of all active, inactive,
21 biological, and synthetic ingredients,
22 b. the origin of any biological materials, specifying
23 whether they are derived from human, animal, or
24 synthetic sources,

- c. the purpose of each ingredient, and
- d. the quantity or concentration of each ingredient, including trace elements and residuals.

2. For products containing mRNA or other gene-based technology,

the disclosure shall specify:

- a. the sequence and source of any nucleic acids, and
- b. the delivery mechanism, including synthetic carriers such as lipid nanoparticles.

B. The ingredient information shall be:

1. Submitted to the State Board of Pharmacy;

2. Published publicly on a manufacturer-maintained website; and
3. Included in product labeling and marketing materials.

C. The responsibility to disclose all ingredients or components

of any pharmaceutical product, medical treatment, or mandate shall

remain unchanged regardless of whether a national emergency is

declared by the President of the United States or Congress. The

rights of individuals shall not be suspended, abridged, or infringed during any declared emergency.

SECTION 3. NEW LAW A new section of law to be codified

in the Oklahoma Statutes as Section 9002.3 of Title 63, unless there

is created a duplication in numbering, reads as follows:

A. Noncompliance with the provisions of this act shall result

in the following penalties:

1 1. Fines up to Fifty Thousand Dollars (\$50,000.00) per
2 violation, per product; and

3 2. Suspension or revocation of the right to distribute or sell
4 the noncompliant pharmaceutical product within this state until
5 compliance is achieved.

6 B. Enhanced penalties for repeated or willful violations shall
7 be assessed as follows:

8 1. Escalating fines:

9 a. on a second violation: fines up to One Hundred
10 Thousand Dollars (\$100,000.00) per product, and

11 b. on a third or subsequent violation: fines up to Two
12 Hundred Fifty Thousand Dollars (\$250,000.00) per
13 product;

14 2. Prohibition of operations: For continued noncompliance, the
15 manufacturer may be prohibited from distributing or selling any
16 pharmaceutical products in this state for up to one (1) year; and

17 3. Criminal liability: Repeated or intentional
18 misrepresentation or omission of ingredient information is a
19 misdemeanor crime punishable by up to one (1) year of imprisonment.

20 C. The following civil remedies shall be available:

21 1. Private right to civil action: Any individual or group
22 harmed by noncompliance with this act, including misrepresentation
23 or omission of ingredient information, may bring a civil lawsuit
24 against the manufacturer for damages including, but not limited to:

1 a. economic damages including, but not limited to,
2 medical expenses or financial losses,
3 b. noneconomic damages including, but not limited to,
4 pain and suffering or emotional distress, and
5 c. punitive damages, as appropriate under Oklahoma law;
6 and

7 2. Class action suit: Affected individuals may form a class to
8 seek collective remedy in cases of widespread harm resulting from
9 noncompliance.

10 D. The State of Oklahoma may seek injunctive relief to compel
11 compliance or halt the distribution and sale of noncompliant
12 pharmaceutical products.

13 E. Individuals who report violations of this act by
14 manufacturers shall be protected from retaliation under applicable
15 whistleblower statutes and may be entitled to a percentage of fines
16 collected as a result of their report.

17 F. The State Board of Pharmacy shall establish a reporting
18 system for individuals to file complaints regarding suspected
19 violations of this act, with such reports forwarded to the
20 Legislature for review and potential enforcement action.

21 SECTION 4. NEW LAW A new section of law to be codified
22 in the Oklahoma Statutes as Section 9002.4 of Title 63, unless there
23 is created a duplication in numbering, reads as follows:

1 The Legislature shall retain exclusive rulemaking authority to
2 implement and enforce the provisions of this act.

3 SECTION 5. NEW LAW A new section of law to be codified
4 in the Oklahoma Statutes as Section 9002.5 of Title 63, unless there
5 is created a duplication in numbering, reads as follows:

6 To the extent any laws conflict with this act, this act shall
7 govern.

8 SECTION 6. This act shall become effective January 1, 2027.

10 60-2-3505

11 BRC

12 1/15/2026 10:26:03 AM

13

14

15

16

17

18

19

20

21

22

23

24